ClinicalTrials.gg

Program

Berzanoflast

Also written as “AZD4144”, “[14C]AZD4144 Solution for Infusion” and “[14C]AZD4144 Oral Solution”.

Its studies are mostly in Sepsis · Kidney Failure, Chronic · Renal Insufficiency, Chronic · Atherosclerosis · Inflammation, led by AstraZeneca.

Furthest: phase 2, since Oct 8, 202511 company-led studies, 2 open or runningNext primary completion: Feb 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca112 open or runningphase 2since Oct 8, 2025Nov 3, 2023Feb 11, 2027phase 2 · NCT07215702
  • Named in AstraZeneca’s own pipeline as AZD4144, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: quotient-sciences and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06122714 · 95 enrolled · United States
  2. Jul 1, 2024Phase 1 study in Healthy ParticipantsNCT06491550 · 91 enrolled · United States
  3. Nov 4, 20242 phase 1 studiesNCT06675175, NCT06693765
  4. Apr 7, 20253 phase 1 studiesNCT06925854, NCT06942923, NCT06948006
  5. Oct 8, 2025Phase 2 study in SepsisNCT07215702 · 124 planned · United States, Argentina, Belgium and more
  6. Feb 10, 2026Phase 1 study in Healthy ParticipantsNCT07518459 · 16 enrolled · United Kingdom
  7. Jun 29, 2026Phase 1 study in HealthyNCT07685600 · 32 enrolled · United Kingdom
  8. Aug 20, 2026Phase 1 study in Hepatic ImpairmentNCT07783308 · 30 planned · United States

Ahead

  1. Feb 11, 2027Primary completion: phase 2 study in SepsisNCT07215702
  2. May 28, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07783308

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07783308Hepatic Impairment · United States1Not yet recruitingMay 28, 202730
NCT07685600Healthy · United Kingdom1CompletedOct 22, 202632
NCT07518459Healthy Participants · United Kingdom1CompletedMay 26, 202616
NCT07215702Sepsis · United States, Argentina, Belgium and more2RecruitingFeb 11, 2027124
NCT06948006Healthy Participants · United Kingdom1CompletedJun 27, 202532
NCT06942923Atherosclerosis · Germany1CompletedSep 29, 202528
NCT06925854Inflammation · United Kingdom1CompletedJun 12, 202512
NCT06693765Renal Insufficiency · Bulgaria, Romania1CompletedApr 23, 202541
NCT06675175Renal Insufficiency, Chronic · United States, Bulgaria, Hungary and more1CompletedOct 27, 202529
NCT06491550Healthy Participants · United States1CompletedJun 11, 202591
NCT06122714Healthy Participants · United States1CompletedDec 4, 202495

How it is read

Names in the registry

  • “AZD4144”, 9 entries
  • “[14C]AZD4144 Solution for Infusion”, 1 entry
  • “[14C]AZD4144 Oral Solution”, 1 entry
  • “AZD4144- Part A”, 1 entry
  • “AZD4144- Part B”, 1 entry

Codes read as this program: AZD4144.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.